Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Oncotype DX Predicts Outcomes in Men With Unfavorable Intermediate-Risk Prostate Cancer, Study Finds

Oncotype DX Predicts Outcomes in Men With Unfavorable Intermediate-Risk Prostate Cancer, Study Finds

Jun 30, 2020
|
Christie Rizk
Premium

NEW YORK – Two new studies are highlighting the utility of Exact Sciences' Oncotype DX Genomic Prostate Score (GPS) assay as an independent predictor of disease outcomes in two different populations: patients with unfavorable intermediate (UFI)-risk prostate cancer, and African American men.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

What's Popular?

In Cancer

  1. Rakuten Medical Sues Illumina Over Trademark Dispute

  2. Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

  3. Natera Revenues Climb 16 Percent in Q2 Driven by Reproductive Health Business

  4. Guardant Health Q2 Revenues Rise 23 Percent

  5. Exact Sciences Positions Itself as Cancer Testing Provider of Future as COVID Crisis Continues

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.